National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: The Need for Pediatric-Specific Long-Term Follow-up Guidelines

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 3, 2012, Pages 334-347

  Pulsipher, Michael A ^a   Skinner, Roderick ^b   McDonald, George B ^c   Hingorani, Sangeeta ^d   Armenian, Saro H ^e   Cooke, Kenneth R ^f   Gracia, Clarisa ^g   Petryk, Anna ^h   Bhatia, Smita ^e   Bunin, Nancy ⁱ   Nieder, Michael L ^j   Dvorak, Christopher C ^k   Sung, Lillian ^l   Sanders, Jean E ^m   Kurtzberg, Joanne ⁿ   Baker, K Scott ^m  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Newcastle Upon Tyne Hospitals NHS Foundation Trust   (United Kingdom)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e City of Hope ^*  (United States)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h UNIVERSITY OF MINNESOTA   (United States)

ⁱ CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^j JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l HOSPITAL FOR SICK CHILDREN   (Canada)

^m USA   (United States)

ⁿ DUKE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Pediatric allogeneic transplantation; Pediatric autologous transplantation; Post transplant organ damage

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; AZITHROMYCIN; BISPHOSPHONIC ACID DERIVATIVE; CALCINEURIN INHIBITOR; CAPTOPRIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUTICASONE; GROWTH HORMONE; LOW MOLECULAR WEIGHT HEPARIN; MONTELUKAST; STATIN; STEROID; TACROLIMUS;

ALBUMINURIA; ANALGESIA; BONE DENSITY; BONE NECROSIS; BRONCHIOLITIS OBLITERANS; CANCER SURVIVOR; CANCER THERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONSENSUS DEVELOPMENT; DRUG MEGADOSE; FOLLOW UP; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; GROWTH DISORDER; HEART DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATOBILIARY DISEASE; HUMAN; HYPERTENSION; INFERTILITY; IRON OVERLOAD; KIDNEY DISEASE; KIDNEY FUNCTION; LIVER BIOPSY; LONG TERM CARE; LUNG DISEASE; MEDICAL SOCIETY; METABOLIC SYNDROME X; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGOSPERMIA; OVARY FUNCTION; OVARY INSUFFICIENCY; PRACTICE GUIDELINE; PROTEINURIA; REPRODUCTION; REVIEW; RISK; SCREENING TEST; THYROID DISEASE;

CHILD; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NATIONAL CANCER INSTITUTE (U.S.); PEDIATRICS; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 84856975123     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.01.003     Document Type: Review

References (90)

1. Baker K.S., Bhatia S., Bunin N., et al. NCI, NHLBI First International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: state of the science, future directions. Biol Blood Marrow Transplant 2011, 17:1424-1427.
2. Bhatia S., Davies S.M., Baker K.S., et al. NCI, NHLBI First International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: etiology and pathogenesis of late effects after HCT performed in childhood-methodologic challenges. Biol Blood Marrow Transplant 2011, 17:1428-1435.
3. Nieder M.L., McDonald G.B., Kida A., et al. National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: long-term organ damage and dysfunction. Biol Blood Marrow Transplant 2011, 17:1573-1584.
4. Dvorak C.C., Gracia C.R., Sanders J.E., et al. NCI, NHLBI/PBMTC First International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Endocrine challenges-thyroid dysfunction, growth impairment, bone health, and reproductive risks. Biol Blood Marrow Transplant 2011, 17:1725-1738.
5. Bunin N., Small T., Szabolcs P., et al. NCI, NHLBI/PBMTC First International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Persistent immune deficiency in pediatric transplant survivors. Biol Blood Marrow Transplant 2012 Jan, 18(1):6-15. Epub 2011 Nov 17.
6. Parsons S.K., Phipps S., Sung L., et al. NCI, NHLBI/PBMTC First International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Health-related quality of life, functional, and neurocognitive outcomes. Biol Blood Marrow Transplant 2012 Feb, 18(2):162-171. Epub 2011 Dec 10.
7. Bhatia S., Francisco L., Carter A., et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007, 110:3784-3792.
8. Bhatia S., Robison L.L., Francisco L., et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood 2005, 105:4215-4222.
9. Martin P.J., Counts G.W., Appelbaum F.R., et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol 2010, 28:1011-1016.
10. Bresters D., Van Gils I.C., Dekker F.W., et al. Abnormal liver enzymes two years after haematopoietic stem cell transplantation in children: prevalence and risk factors. Bone Marrow Transplant 2008, 41:27-31.
11. Faraci M., Barra S., Cohen A., et al. Very late nonfatal consequences of fractionated TBI in children undergoing bone marrow transplant. Int J Radiat Oncol Biol Phys 2005, 63:1568-1575.
12. Ferry C., Gemayel G., Rocha V., et al. Long-term outcomes after allogeneic stem cell transplantation for children with hematological malignancies. Bone Marrow Transplant 2007, 40:219-224.
13. Leahey A.M., Teunissen H., Friedman D.L., et al. Late effects of chemotherapy compared to bone marrow transplantation in the treatment of pediatric acute myeloid leukemia and myelodysplasia. Med Pediatr Oncol 1999, 32:163-169.
14. Perkins J.L., Kunin-Batson A.S., Youngren N.M., et al. Long-term follow-up of children who underwent hematopoeitic cell transplant (HCT) for AML or ALL at less than 3 years of age. Pediatr Blood Cancer 2007, 49:958-963.
15. Majhail N.S., Rizzo J.D., Lee S.J., et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012, 18:348-371.
16. Rizzo J.D., Wingard J.R., Tichelli A., et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2006, 12:138-151.
17. Hentze M.W., Muckenthaler M.U., Andrews N.C. Balancing acts: molecular control of mammalian iron metabolism. Cell 2004, 117:285-297.
18. Lucarelli G., Angelucci E., Giardini C., et al. Fate of iron stores in thalassaemia after bone-marrow transplantation. Lancet 1993, 342:1388-1391.
19. Chotsampancharoen T., Gan K., Kasow K.A., et al. Iron overload in survivors of childhood leukemia after allogeneic hematopoietic stem cell transplantation. Pediatr Transplant 2009, 13:348-352.
20. Angelucci E., Muretto P., Lucarelli G., et al. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients. Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Blood 1997, 90:994-998.
21. Mariotti E., Angelucci E., Agostini A., et al. Evaluation of cardiac status in iron-loaded thalassaemia patients following bone marrow transplantation: improvement in cardiac function during reduction in body iron burden. Br J Haematol 1998, 103:916-921.
22. Angelucci E., Muretto P., Lucarelli G., et al. Treatment of iron overload in the "ex-thalassemic": report from the phlebotomy program. Ann NY Acad Sci 1998, 850:288-293.
23. McDonald G.B. Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. Hepatology 2010, 51:1450-1460.
24. Cohen E.P., Irving A.A., Drobyski W.R., et al. Captopril to mitigate chronic renal failure after hematopoietic stem cell transplantation: a randomized controlled trial. Int J Radiat Oncol Biol Physics 2008, 70:1546-1551.
25. Chien J.W., Martin P.J., Flowers M.E., et al. Implications of early airflow decline after myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2004, 33:759-764.
26. Chien J.W., Duncan S., Williams K.M., et al. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation: an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2010, 16(1 Suppl):S106-S114.
27. Hildebrandt G.C., Fazekas T., Lawitschka A., et al. Diagnosis and treatment of pulmonary chronic GVHD: report from the Consensus Conference on Clinical Practice in Chronic GVHD. Bone Marrow Transplant 2011, 46:1283-1295.
28. Cooke K.R., Yanik G. Lung injury following hematopoietic stem cell transplantation. Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation 2009, Wiley-Blackwell, Oxford, UK. 4th ed. F.M. Applebaum, S.J. Forman, R.S. Negrin (Eds.).
29. Yanik G.A., Mineishi S., Levine J.E., et al. Soluble tumor necrosis factor receptor: Enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2011, [Epub ahead of print].
30. Norman B.C., Jacobsohn D.A., Williams K.M., et al. Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients. Bone Marrow Transplant 2011, 46:1369-1373.
31. van Dalen E.C., van der Pal H.J., Kok W.E., et al. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur J Cancer 2006, 42:3191-3198.
32. Oeffinger K.C., Mertens A.C., Sklar C.A., et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006, 355:1572-1582.
33. Armenian S.H., Sun C.L., Francisco L., et al. Late congestive heart failure after hematopoietic cell transplantation. J Clin Oncol 2008, 26:5537-5543.
34. Armenian S.H., Sun C.L., Kawashima T., et al. Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). Blood 2011, 118:1413-1420.
35. Armenian S.H., Sun C.L., Mills G., et al. Predictors of late cardiovascular complications in survivors of hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010, 16:1138-1144.
36. Katsanis E., Shapiro R., Robison L., et al. Thyroid dysfunction following bone marrow transplantation: long-term follow-up of 80 pediatric patients. Bone Marrow Transplant 1990, 5:335-340.
37. Sanders J., Hoffmeister P., Woolfrey A., et al. Thyroid function following hematopoietic cell transplantation in children: 30 years' experience. Blood 2009, 113:306-308.
38. Huma Z., Boulad F., Black P., et al. Growth in children after bone marrow transplantation for acute leukemia. Blood 1995, 86:819-824.
39. Sanders J., Guthrie K., Hoffmeister P., et al. Final adult height of patients who received hematopoietic cell transplantation in childhood. Blood 2005, 105:1348-1354.
40. McClune B.L., Polgreen L.E., Burmeister L.A., et al. Screening, prevention and management of osteoporosis and bone loss in adult and pediatric hematopoietic cell transplant recipients. Bone Marrow Transplant 2011, 46:1-9.
41. Wasilewski-Masker K., Kaste S.C., Hudson M.M., et al. Bone mineral density deficits in survivors of childhood cancer: long-term follow-up guidelines and review of the literature. Pediatrics 2008, 121:e705-e713.
42. Misra M., Pacaud D., Petryk A., et al. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics 2008, 122:398-417.
43. Gordon C.M., Williams A.L., Feldman H.A., et al. Treatment of hypovitaminosis D in infants and toddlers. J Clin Endocrinol Metab 2008, 93:2716-2721.
44. Bishop N., Braillon P., Burnham J., et al. Dual-energy X-ray aborptiometry assessment in children and adolescents with diseases that may affect the skeleton: the 2007 ISCD Pediatric Official Positions. J Clin Densitom 2008, 11:29-42.
45. Carpenter P., Hoffmeister P., Chesnut C., et al. Bisphosphonate therapy for reduced bone mineral density in children with chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007, 13:683-690.
46. Kananen K., Volin L., Laitinen K., et al. Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate. J Clin Endocrinol Metab 2005, 90:3877-3885.
47. Grigg A.P., Shuttleworth P., Reynolds J., et al. Pamidronate reduces bone loss after allogeneic stem cell transplantation. J Clin Endocrinol Metab 2006, 91:3835-3843.
48. Russell R.G. Bisphosphonates: mode of action and pharmacology. Pediatrics 2007, 1199(Suppl 20):S150-S162.
49. Ward L.M., Petryk A., Gordon C.M. Use of bisphosphonates in the treatment of pediatric osteoporosis. Int J Clin Rheumatol 2009, 4:657-672.
50. Marston S., Gillingham K., Bailey R., et al. A prospective study of osteonecrosis of the femoral head in solid organ transplantation patients. J BoneJoint Surg Am 2002, 84:2145-2151.
51. Musso E.S., Mitchell S.N., Schink-Ascani M., et al. Results of conservative management of osteonecrosis of the femoral head: a retrospective review. Clin Orthop Relat Res 1986, 207:209-215.
52. Hungerford D.S., Jones L.C. Asymptomatic osteonecrosis: should it be treated?. Clin Orthop Relat Res 2004, 429:124-130.
53. Wiesmann A., Pereira P., Bohm P., et al. Avascular necrosis of bone following allogeneic stem cell transplantation: MR screening and therapeutic options. Bone Marrow Transplant 1998, 22:565-569.
54. Cheng E., Thongtrangan I., Laorr A., et al. Spontaneous resolution of osteonecrosis of the femoral head. J Bone Joint Surg Am 2004, 86:2594-2599.
55. Assouline-Dayan Y., Chang C., Greenspan A., et al. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 2002, 32:94-124.
56. Burger B., Beier R., Zimmermann M., et al. Osteonecrosis: a treatment-related toxicity in childhood acute lymphoblastic leukemia (ALL): experiences from trial ALL-BFM 95. Pediatr Blood Cancer 2005, 44:220-225.
57. Kaste S.C., Shidler T.J., Tong X., et al. Bone mineral density and osteonecrosis in survivors of childhood allogeneic bone marrow transplantation. Bone Marrow Transplant 2004, 33:435-441.
58. Li Z., Zhang N., Yue D. Experimental steroid osteonecrosis in rabbits and pathologic findings. Zhonghua Wai Ke Za Zhi 1995, 33:485-487. (in Chinese).
59. Cui Q., Wang G.J., Su C.C., et al. The Otto Aufranc Award: lovastatin prevents steroid-induced adipogenesis and osteonecrosis. Clin Orthop Relat Res 1997, 344:8-19.
60. Pritchett J.W. Statin therapy decreases the risk of osteonecrosis in patients receiving steroids. Clin Orthop Relat Res 2001, 386:173-178.
61. Ajmal M., Matas A.J., Kuskowski M., et al. Does statin usage reduce the risk of corticosteroid-related osteonecrosis in renal transplant population?. Orthop Clin North Am 2009, 40:235-239.
62. Edwards C.J., Hart D.J., Spector T.D. Oral statins and increased bone-mineral density in postmenopausal women. Lancet 2000, 355:2218-2219.
63. Glueck C.J., Freiberg R.A., Sieve L., et al. Enoxaparin prevents progression of stages I and II osteonecrosis of the hip. Clin Orthop Relat Res 2005, 435:164-170.
64. Lefkou E., Khamashta M., Hampson G., et al. Review: Low-molecular-weight heparin-induced osteoporosis and osteoporotic fractures: a myth or an existing entity?. Lupus 2010, 19:3-12.
65. Lai K.A., Shen W.J., Yang C.Y., et al. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis: a randomized clinical study. J Bone Joint Surg Am 2005, 87:2155-2159.
66. Nguyen T., Zacharin M.R. Pamidronate treatment of steroid associated osteonecrosis in young patients treated for acute lymphoblastic leukaemia: two-year outcomes. J Pediatr Endocrinol Metab 2006, 19:161-167.
67. Nishii T., Sugano N., Miki H., et al. Does alendronate prevent collapse in osteonecrosis of the femoral head?. Clin Orthop Relat Res 2006, 443:273-279.
68. Ramachandran M., Ward K., Brown R.R., et al. Intravenous bisphosphonate therapy for traumatic osteonecrosis of the femoral head in adolescents. J Bone Joint Surg Am 2007, 89:1727-1734.
69. Gangji V., Hauzeur J.P., Matos C., et al. Treatment of osteonecrosis of the femoral head with implantation of autologous bone marrow cells: a pilot study. J Bone Joint Surg Am 2004, 86:1153-1160.
70. Hernigou P., Poignard A., Manicom O., et al. The use of percutaneous autologous bone marrow transplantation in nonunion and avascular necrosis of bone. J Bone Joint Surg Br 2005, 87:896-902.
71. Hernigou P., Beaujean F., Lambotte J.C. Decrease in the mesenchymal stem-cell pool in the proximal femur in corticosteroid-induced osteonecrosis. J Bone Joint Surg Br 1999, 81:349-355.
72. Leung W., Ahn H., Rose S.R., et al. A prospective cohort study of late sequelae of pediatric allogeneic hematopoietic stem cell transplantation. Medicine (Baltimore) 2007, 86:215-224.
73. Sklar C. Reproductive physiology and treatment-related loss of sex hormone production. Med Pediatr Oncol 1999, 33:2-8.
74. Byrne J., Fears T.R., Gail M.H., et al. Early menopause in long-term survivors of cancer during adolescence. Am J Obstet Gynecol 1992, 166:788-793.
75. Byrne J. Infertility and premature menopause in childhood cancer survivors. Med Pediatr Oncol 1999, 33:24-28.
76. Kreuser E.D., Felsenberg D., Behles C., et al. Long-term gonadal dysfunction and its impact on bone mineralization in patients following COPP/ABVD chemotherapy for Hodgkin's disease. Ann Oncol 1992, 3(Suppl 4):105-110.
77. Lie Fong S., Lugtenburg P.J., Schipper I., et al. Anti-mullerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies. Hum Reprod 2008, 23:674-678.
78. Larsen E.C., Muller J., Schmiegelow K., et al. Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer. J Clin Endocrinol Metab 2003, 88:5307-5314.
79. Bath L.E., Wallace W.H., Shaw M.P., et al. Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound. Hum Reprod 2003, 18:2368-2374.
80. Giuseppe L., Attilio G., Edoardo D.N., et al. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology 2007, 12:141-147.
81. van Beek R.D., van den Heuvel-Eibrink M.M., Laven J.S., et al. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood. J Clin Endocrinol Metab 2007, 92:3869-3874.
82. Larsen E.C., Muller J., Rechnitzer C., et al. Diminished ovarian reserve in female childhood cancer survivors with regular menstrual cycles and basal FSH <10 IU/L. Hum Reprod 2003, 18:417-422.
83. Piccioni P., Scirpa P., D'Emilio I., et al. Hormonal replacement therapy after stem cell transplantation. Maturitas 2004, 49:327-333.
84. Castelo-Branco C., Rovira M., Pons F., et al. The effect of hormone replacement therapy on bone mass in patients with ovarian failure due to bone marrow transplantation. Maturitas 1996, 23:307-312.
85. Rebar R.W. Premature ovarian failure. Obstet Gynecol 2009, 113:1355-1363.
86. Sanders J.E. Growth and development after hematopoietic cell transplant in children. Bone Marrow Transplant 2008, 41:223-227.
87. Ginsburg E.S., Yanushpolsky E.H., Jackson K.V. Invitro fertilization for cancer patients and survivors. Fertil Steril 2001, 75:705-710.
88. Sanders J.E., Hawley J., Levy W., et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood 1996, 87:3045-3052.
89. Gracia C.R. Reproductive health after cancer. Cancer Treat Res 2010, 156:3-9.
90. Sanders J.E., Woolfrey A.E., Carpenter P.A., et al. Late effects among pediatric patients followed for nearly 4 decades after transplantation for severe aplastic anemia. Blood 2011, 118:1421-1428.